{
    "A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses": "7822889",
    "A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529)": "9869787",
    "A Na\u00efve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern": "10588750",
    "A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies": "8465657",
    "A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo": "8748511",
    "A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration": "9734137",
    "A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug": "11211474",
    "A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies": "8448731",
    "A high-affinity RBD-targeting nanobody improves fusion partner\u2019s potency against SARS-CoV-2": "7959386",
    "A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike": "9365158",
    "A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants": "8564274",
    "A novel strategy for an anti-idiotype vaccine: nanobody mimicking neutralization epitope of porcine circovirus type 2": "10878242",
    "A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron": "9257560",
    "A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19": "8458290",
    "A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants": "8863326",
    "A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode": "9479348",
    "A single domain antibody-based Luminex assay for the detection of SARS-CoV-2 in clinical samples": "11347438",
    "A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity": "11148769",
    "A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection": "8324831",
    "Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants": "9288967",
    "Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant": "8877688",
    "An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion": "9407951",
    "An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction": "7473855",
    "An extended conformation of SARS-CoV-2 main protease reveals allosteric targets": "9169858",
    "An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation": "7430568",
    "An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants": "8828845",
    "An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike": "7857409",
    "Angiotensin-Converting Enzyme 2-Based Biosensing Modalities and Devices for Coronavirus Detection": "9688389",
    "Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design": "7854682",
    "Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions": "9150821",
    "Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination": "11003867",
    "Antibody-like proteins that capture and neutralize SARS-CoV-2": "7556756",
    "Antibody-mediated immunity to SARS-CoV-2 spike": "9393763",
    "Applications of nanobodies in the prevention, detection, and treatment of the evolving SARS-CoV-2": "9801699",
    "Aptamers and Nanobodies as New Bioprobes for SARS-CoV-2 Diagnostic and Therapeutic System Applications": "10968798",
    "Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models": "9461429",
    "Backstage Heroes-Yeast in COVID-19 Research": "11640846",
    "Biomimetic Nanotechnology for SARS-CoV-2 Treatment": "10051120",
    "Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals": "9481167",
    "Biparatopic nanobodies protect mice from lethal challenge with SARS\u2010CoV\u20102 variants of concern": "8811630",
    "Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2": "9529347",
    "Biparatopic sybodies neutralize SARS\u2010CoV\u20102 variants of concern and mitigate drug resistance": "8982573",
    "Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern": "11100608",
    "Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article": "8768012",
    "Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening": "10373554",
    "Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody": "8907017",
    "Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses": "9792944",
    "COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies": "8301790",
    "Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration": "8699001",
    "Circular RNA vaccines against SARS-CoV-2 and emerging variants": "8971115",
    "Comparative Study of the Mutations Observed in the SARS-CoV-2 RBD Variants of Concern and Their Impact on the Interaction with the ACE2 Protein": "10578311",
    "Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants": "11209230",
    "Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2": "10597523",
    "Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies": "9355996",
    "Construction and validation of a synthetic phage-displayed nanobody library": "11361996",
    "Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes": "9351521",
    "Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants": "8476643",
    "Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)": "11228696",
    "Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift": "9132424",
    "Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization": "10688893",
    "Development of a platform process for the production and purification of single\u2010domain antibodies": "8451865",
    "Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein": "7844813",
    "Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies": "8344751",
    "Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis": "8223476",
    "Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening": "8528929",
    "Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants": "10444775",
    "Discovery of Nanosota-9 as anti-Omicron nanobody therapeutic candidate": "11630572",
    "Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years": "11515141",
    "Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants": "9170159",
    "Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2": "8021111",
    "Dual-role epitope on SARS-CoV-2 spike enhances and neutralizes viral entry across different variants": "11407660",
    "Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients": "8368053",
    "Emerging Landscape of Nanobodies and Their Neutralizing Applications against SARS-CoV-2 Virus": "10275483",
    "Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance": "8606259",
    "Emerging trends in point-of-care biosensing strategies for molecular architectures and antibodies of SARS-CoV-2": "9941073",
    "Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1": "11054741",
    "Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain": "11091055",
    "Epitope profiling using computational structural modelling demonstrated on coronavirus-binding antibodies": "8700021",
    "Evaluation of an Affinity-Enhanced Anti-SARS-CoV2 Nanobody Design Workflow Using Machine Learning and Molecular Dynamics": "11481066",
    "Expanding and improving nanobody repertoires using a yeast display method: Targeting SARS-CoV-2": "9884143",
    "Fragment-based computational design of antibodies targeting structured epitopes": "9651861",
    "Fully synthetic platform to rapidly generate tetravalent bispecific nanobody-based immunoglobulins": "10268213",
    "Generation of nanobodies acting as silent and positive allosteric modulators of the \u03b17 nicotinic acetylcholine receptor": "10213069",
    "Generation of nanobodies from transgenic \u2018LamaMice\u2019 lacking an endogenous immunoglobulin repertoire": "11148044",
    "Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron": "9334538",
    "High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme": "7755911",
    "Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape": "8651292",
    "Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain": "7483421",
    "ISEV2024 Abstract Book": "11245638",
    "Identification of Human Single-Domain Antibodies against SARS-CoV-2": "7224157",
    "Identification of nurse shark VNAR single-domain antibodies targeting the spike S2 subunit of SARS-CoV-2": "10715488",
    "In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2": "10702856",
    "Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment": "8061467",
    "Isolation and characterization of single domain antibodies from banded houndshark (Triakis scyllium) targeting SARS-CoV-2 spike RBD protein": "10167778",
    "Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library": "9524272",
    "Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2": "9020654",
    "K205R specific nanobody-horseradish peroxidase fusions as reagents of competitive ELISA to detect African swine fever virus serum antibodies": "9392344",
    "Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic": "8006950",
    "Lys417 acts as a molecular switch that regulates the conformation of SARS-CoV-2 spike protein": "10695562",
    "Mechanisms of SARS-CoV-2 entry into cells": "8491763",
    "Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy": "8193598",
    "Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern": "8906176",
    "Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection": "8724751",
    "Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern": "8782626",
    "Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants": "9512078",
    "Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies": "8956255",
    "NABP-BERT: NANOBODY\u00ae-antigen binding prediction based on bidirectional encoder representations from transformers (BERT) architecture": "11650500",
    "NanoLAS: a comprehensive nanobody database with data integration, consolidation and application": "10833066",
    "NanoNet: Rapid and accurate end-to-end nanobody modeling by deep learning": "9411858",
    "Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron": "9082315",
    "Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants": "10054972",
    "Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view": "8325376",
    "Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants": "8260353",
    "Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons": "11108896",
    "Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models": "10590698",
    "Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review": "7832525",
    "Nanobodies: From High-Throughput Identification to Therapeutic Development": "11609455",
    "Nanobodies: a promising approach to treatment of viral diseases": "10844482",
    "Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2": "8043454",
    "Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice": "8126837",
    "Nanobody derived using a peptide epitope from the spike protein receptor-binding motif inhibits entry of SARS-CoV-2 variants": "9678391",
    "Nanobody engineering for SARS-CoV-2 neutralization and detection": "10986514",
    "Nanobody engineering: computational modelling and design for biomedical and therapeutic applications": "11788755",
    "Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus": "11076045",
    "Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies": "11793827",
    "Nanobody-peptide-conjugate (NPC) for passive immunotherapy against SARS-CoV-2 variants of concern (VoC): a prospective pan-coronavirus therapeutics": "9676808",
    "Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19": "8597880",
    "Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19": "8928829",
    "Neutralization of SARS\u2010CoV\u20102 by highly potent, hyperthermostable, and mutation\u2010tolerant nanobodies": "8420576",
    "Neutralizing Dromedary-Derived Nanobodies Against BotI-Like Toxin From the Most Hazardous Scorpion Venom in the Middle East and North Africa Region": "9063451",
    "Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies": "10301551",
    "NeutrobodyPlex-monitoring SARS\u2010CoV\u20102 neutralizing immune responses using nanobodies": "8097376",
    "Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules": "9181103",
    "Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review": "8730734",
    "Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology": "7642257",
    "Perturbation of the host cell Ca2+ homeostasis and ER-mitochondria contact sites by the SARS-CoV-2 structural proteins E and M": "10148623",
    "Plant virus\u2010derived nanoparticles decorated with genetically encoded SARS\u2010CoV\u20102 nanobodies display enhanced neutralizing activity": "10955499",
    "Plant-derived single domain COVID-19 antibodies": "10231691",
    "Plasmonic Approaches for the Detection of SARS-CoV-2 Viral Particles": "9313406",
    "Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection": "8201996",
    "Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain": "8139655",
    "Potent Therapeutic Strategies for COVID-19 with Single-Domain Antibody Immunoliposomes Neutralizing SARS-CoV-2 and Lip/cGAMP Enhancing Protective Immunity": "9966208",
    "Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody": "7870875",
    "Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes": "8333356",
    "Production and purification of shark and camel single domain antibodies from bacterial and mammalian cell expression systems": "9219022",
    "Prospects for the computational humanization of antibodies and nanobodies": "11133524",
    "Quantitative Assessment of Energetic Contributions of Residues in a SARS-CoV-2 Viral Enzyme/Nanobody Interface": "10966652",
    "Rapid and Quantitative In-vitro Evaluation of SARS-CoV-2 Neutralizing Antibodies and Nanobodies": "9356539",
    "Rapid covalent labeling of membrane proteins on living cells using a nanobody-epitope tag pair": "10200341",
    "Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries": "8726723",
    "Rapid generation of potent antibodies by autonomous hypermutation in yeast": "8463502",
    "Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis": "8924699",
    "Research progress and applications of nanobody in human infectious diseases": "9411660",
    "Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies": "10060843",
    "SARS-CoV-2 Delta Variant Decreases Nanobody Binding and ACE2 Blocking Effectivity": "9113008",
    "SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice": "10892724",
    "SARS-CoV-2 and the host-immune response": "10315470",
    "SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses": "9900178",
    "SARS-CoV-2: Origin, Evolution, and Targeting Inhibition": "8248807",
    "Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein": "9656363",
    "Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2": "7642358",
    "Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant": "9491202",
    "Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies": "10891761",
    "Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity": "9896449",
    "Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22)": "8967979",
    "Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses": "9482557",
    "Single domain antibodies from camelids in the treatment of microbial infections": "11140111",
    "Single domain antibody: Development and application in biotechnology and biopharma": "11659936",
    "Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern": "8907979",
    "Single-Domain Antibodies and Their Formatting to Combat Viral Infections": "6640686",
    "Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections": "9230756",
    "Single-Domain Antibodies-Novel Tools to Study and Treat Allergies": "11277559",
    "Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries": "10865538",
    "Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time": "7744031",
    "Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies": "7833398",
    "Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies": "7199733",
    "Structural Basis for SARS-CoV-2 Nucleocapsid Protein Recognition by Single-Domain Antibodies": "8351461",
    "Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2": "8625641",
    "Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering": "8951411",
    "Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants": "8853550",
    "Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2": "11285730",
    "Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies": "11228396",
    "Structural basis of nanobodies neutralizing SARS-CoV-2 variants": "8908544",
    "Structural biology of SARS-CoV-2 and implications for therapeutic development": "8447893",
    "Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19": "8771608",
    "Structure-guided in vitro evolution of nanobodies targeting new viral variants": "11460708",
    "Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape": "7932109",
    "Super broad and protective nanobodies against Sarbecoviruses including SARS-CoV-1 and the divergent SARS-CoV-2 subvariant KP.3.1.1": "11554226",
    "Superimmunity by pan-sarbecovirus nanobodies": "9174178",
    "Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies": "10858526",
    "The Development of a Novel Nanobody Therapeutic for SARS-CoV-2": "7685322",
    "The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics": "9850341",
    "The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates": "8354634",
    "The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization": "8514607",
    "Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: Current update": "9797221",
    "Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses": "11140877",
    "Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice": "9834170",
    "Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease": "8221914",
    "Uncovering a conserved vulnerability site in SARS\u2010CoV\u20102 by a human antibody": "8646660",
    "Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2": "10518403",
    "Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases": "7112682",
    "Using Homology Modeling to Interrogate Binding Affinity in Neutralization of Ricin Toxin by a Family of Single Domain Antibodies": "5754017",
    "Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2": "7857400",
    "Visual and High-Efficiency Secretion of SARS-CoV-2 Nanobodies with Escherichia coli": "11762740"
}